Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?

Avcilar, Huseyin; Eken, Ahmet

Avcilar, Huseyin; Eken, Ahmet.

Avcilar H; Erciyes University, Immunology Department, Faculty of Medicine, Kayseri, Turkey. Electronic address: havcilar13@gmail.com.
Eken A; Betul-Ziya Eren Genome and Stem Cell Center, Kayseri, Turkey; Erciyes University, Medical Biology Department, Faculty of Medicine, Kayseri, Turkey. Electronic address: ahmet.eken@gmail.com.

Med Hypotheses ; 144: 110202, 2020 Nov.

Article in English | MEDLINE | ID: covidwho-741421

ABSTRACT

ABSTRACT

Toll-like receptor 7 is critical in recognition of single strand RNA viruses, including SARS CoV-2, and generation of anti-viral immunity. Coronaviruses evolved strategies to dampen the host immunity. Herein, we discuss the potential use of TLR7 agonists in the early stages of COVID-19 treatment.

Subject(s)

Antiviral Agents/therapeutic use; COVID-19 Drug Treatment; Imiquimod/therapeutic use; Toll-Like Receptor 7/agonists; Adjuvants, Immunologic/administration & dosage; Adjuvants, Immunologic/therapeutic use; Antiviral Agents/administration & dosage; COVID-19/immunology; Humans; Imiquimod/administration & dosage; Immunity, Innate/drug effects; Models, Immunological; Pandemics; SARS-CoV-2; Skin Cream

Keywords

COVID-19; Imiquimod; SARS CoV-2; TLR7

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Toll-Like Receptor 7 / Imiquimod / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Med Hypotheses Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google